Complex and alternate consent pathways in clinical trials: methodological and ethical challenges encountered by underserved groups and a call to action.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
28 Feb 2023
Historique:
received: 01 10 2022
accepted: 09 02 2023
entrez: 1 3 2023
pubmed: 2 3 2023
medline: 3 3 2023
Statut: epublish

Résumé

Informed consent is considered a fundamental requirement for participation in trials, yet obtaining consent is challenging in a number of populations and settings. This may be due to participants having communication or other disabilities, their capacity to consent fluctuates or they lack capacity, or in emergency situations where their medical condition or the urgent nature of the treatment precludes seeking consent from either the participant or a representative. These challenges, and the subsequent complexity of designing and conducting trials where alternative consent pathways are required, contribute to these populations being underserved in research. Recognising and addressing these challenges is essential to support trials involving these populations and ensure that they have an equitable opportunity to participate in, and benefit from, research. Given the complex nature of these challenges, which are encountered by both adults and children, a cross-disciplinary approach is required. A UK-wide collaboration, a sub-group of the Trial Conduct Working Group in the MRC-NIHR Trial Methodology Research Partnership, was formed to collectively address these challenges. Members are drawn from disciplines including bioethics, qualitative research, trials methodology, healthcare professions, and social sciences. This commentary draws on our collective expertise to identify key populations where particular methodological and ethical challenges around consent are encountered, articulate the specific issues arising in each population, summarise ongoing and completed research, and identify targets for future research. Key populations include people with communication or other disabilities, people whose capacity to consent fluctuates, adults who lack the capacity to consent, and adults and children in emergency and urgent care settings. Work is ongoing by the sub-group to create a database of resources, to update NIHR guidance, and to develop proposals to address identified research gaps. Collaboration across disciplines, sectors, organisations, and countries is essential if the ethical and methodological challenges surrounding trials involving complex and alternate consent pathways are to be addressed. Explicating these challenges, sharing resources, and identifying gaps for future research is an essential first step. We hope that doing so will serve as a call to action for others seeking ways to address the current consent-based exclusion of underserved populations from trials.

Sections du résumé

BACKGROUND BACKGROUND
Informed consent is considered a fundamental requirement for participation in trials, yet obtaining consent is challenging in a number of populations and settings. This may be due to participants having communication or other disabilities, their capacity to consent fluctuates or they lack capacity, or in emergency situations where their medical condition or the urgent nature of the treatment precludes seeking consent from either the participant or a representative. These challenges, and the subsequent complexity of designing and conducting trials where alternative consent pathways are required, contribute to these populations being underserved in research. Recognising and addressing these challenges is essential to support trials involving these populations and ensure that they have an equitable opportunity to participate in, and benefit from, research. Given the complex nature of these challenges, which are encountered by both adults and children, a cross-disciplinary approach is required.
DISCUSSION CONCLUSIONS
A UK-wide collaboration, a sub-group of the Trial Conduct Working Group in the MRC-NIHR Trial Methodology Research Partnership, was formed to collectively address these challenges. Members are drawn from disciplines including bioethics, qualitative research, trials methodology, healthcare professions, and social sciences. This commentary draws on our collective expertise to identify key populations where particular methodological and ethical challenges around consent are encountered, articulate the specific issues arising in each population, summarise ongoing and completed research, and identify targets for future research. Key populations include people with communication or other disabilities, people whose capacity to consent fluctuates, adults who lack the capacity to consent, and adults and children in emergency and urgent care settings. Work is ongoing by the sub-group to create a database of resources, to update NIHR guidance, and to develop proposals to address identified research gaps.
CONCLUSION CONCLUSIONS
Collaboration across disciplines, sectors, organisations, and countries is essential if the ethical and methodological challenges surrounding trials involving complex and alternate consent pathways are to be addressed. Explicating these challenges, sharing resources, and identifying gaps for future research is an essential first step. We hope that doing so will serve as a call to action for others seeking ways to address the current consent-based exclusion of underserved populations from trials.

Identifiants

pubmed: 36855178
doi: 10.1186/s13063-023-07159-6
pii: 10.1186/s13063-023-07159-6
pmc: PMC9973248
doi:

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

151

Subventions

Organisme : Chief Scientist Office
ID : HSRU1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K025643/1
Pays : United Kingdom

Informations de copyright

© 2023. The Author(s).

Références

Trials. 2020 Jan 21;21(1):104
pubmed: 31964408
BMJ Open. 2015 Sep 18;5(9):e008522
pubmed: 26384724
Health Technol Assess. 2019 Sep;23(47):1-176
pubmed: 31524133
Trials. 2020 May 29;21(1):445
pubmed: 32471488
J Intellect Disabil Res. 2021 Jan;65(1):47-59
pubmed: 33043518
Trials. 2021 Sep 03;22(1):589
pubmed: 34479612
Br J Nurs. 2020 Aug 13;29(15):908-909
pubmed: 32790552
Intensive Care Med. 2014 Apr;40(4):496-503
pubmed: 24570266
Front Neurol. 2011 Oct 17;2:65
pubmed: 22022320
Shock. 2011 Feb;35(2):107-13
pubmed: 20926987
Trials. 2022 May 12;23(1):384
pubmed: 35550642
N Engl J Med. 2021 Oct 7;385(15):1429-1430
pubmed: 34516052
Qual Health Res. 2021 Jun;31(7):1260-1274
pubmed: 33645331
Int J Stroke. 2022 Jun;17(5):553-558
pubmed: 34292119
J Med Ethics. 2018 Sep;44(9):632-637
pubmed: 29695407
BMJ Open. 2021 Sep 22;11(9):e048193
pubmed: 34551943
Can J Psychiatry. 2016 Jun;61(6):335-9
pubmed: 27254842
Trials. 2019 Apr 25;20(1):233
pubmed: 31023383
Top Stroke Rehabil. 2014 Sep-Oct;21(5):443-51
pubmed: 25341389
Age Ageing. 2019 Jul 1;48(4):474-475
pubmed: 31081505
Int J Antimicrob Agents. 2013 Nov;42(5):436-42
pubmed: 24055255
J Intellect Disabil Res. 2014 Sep;58(9):800-9
pubmed: 24001184
Neurology. 2017 Sep 26;89(13):1400-1407
pubmed: 28842449
Am J Psychiatry. 2006 Aug;163(8):1323-34
pubmed: 16877642
Lancet. 2011 Mar 26;377(9771):1071-2
pubmed: 21439634
Age Ageing. 2019 Nov 1;48(6):903-909
pubmed: 31595291
Can J Surg. 2014 Aug;57(4):E141-5
pubmed: 25078940
Int J Ment Health Nurs. 2014 Dec;23(6):513-24
pubmed: 24891249
Age Ageing. 2019 Jul 1;48(4):489-497
pubmed: 31220202
Trials. 2014 Jan 23;15:32
pubmed: 24456928
Lancet. 2019 May 25;393(10186):2125-2134
pubmed: 31005385
Trials. 2022 May 16;23(1):411
pubmed: 35578362
Am J Psychiatry. 2001 May;158(5):712-7
pubmed: 11329391
IRB. 2003 May-Jun;25(3):9-11
pubmed: 14569988
Lancet Neurol. 2019 Sep;18(9):821-833
pubmed: 31397288
Health Expect. 2021 Feb;24(1):152-164
pubmed: 33245186
Ann Transl Med. 2017 Dec;5(Suppl 4):S41
pubmed: 29302597
JAMA. 2018 Jan 23;319(4):337-338
pubmed: 29285540
Neurology. 2012 May 8;78(19):1472-8
pubmed: 22496195
Top Stroke Rehabil. 2006 Fall;13(4):42-6
pubmed: 17082168
Pilot Feasibility Stud. 2019 Jan 22;5:14
pubmed: 30693094
MDM Policy Pract. 2019 Mar 28;4(1):2381468319840322
pubmed: 30944886
Trials. 2011 Mar 31;12:90
pubmed: 21453454
Trials. 2006 May 11;7:13
pubmed: 16689989
Trials. 2020 Aug 1;21(1):694
pubmed: 32738919
J Cancer Educ. 2021 Dec;36(6):1248-1252
pubmed: 32385740
Trials. 2022 Nov 24;23(1):957
pubmed: 36434661
Trials. 2008 Jul 21;9:45
pubmed: 18644120
Contemp Clin Trials. 2015 Sep;44:20-25
pubmed: 26188162
Age Ageing. 2018 Nov 1;47(6):778-784
pubmed: 30010696
BMC Med Ethics. 2021 Aug 14;22(1):111
pubmed: 34391415
JAMA. 2022 Feb 8;327(6):546-558
pubmed: 35072713
Int Psychogeriatr. 2013 Nov;25(11):1821-30
pubmed: 23927951
Dementia (London). 2021 Jan;20(1):308-325
pubmed: 31653184
BMC Med Ethics. 2019 May 7;20(1):30
pubmed: 31064358
BMC Med Ethics. 2016 Sep 08;17(1):55
pubmed: 27609355
Arch Dis Child. 2014 Nov;99(11):1043-9
pubmed: 24919710
J Gerontol B Psychol Sci Soc Sci. 2007 Jan;62(1):P3-P11
pubmed: 17284555
Disabil Rehabil. 2016;38(11):1107-14
pubmed: 26458145
BMC Med Ethics. 2019 Nov 27;20(1):88
pubmed: 31775727
J Pain Symptom Manage. 2003 Apr;25(4):S6-13
pubmed: 12691692
Epidemiology. 2016 May;27(3):389-92
pubmed: 27035689
J Med Ethics. 2020 Sep 2;:
pubmed: 32878918
Trials. 2022 Jun 6;23(1):471
pubmed: 35668460
BMC Med Inform Decis Mak. 2021 Jan 28;21(1):30
pubmed: 33509169
Arch Dis Child Educ Pract Ed. 2016 Feb;101(1):49-53
pubmed: 26464416
J Pediatr. 2018 Jan;192:13-21
pubmed: 28942898
J Med Ethics. 2006 Jan;32(1):61-2
pubmed: 16373526
BMJ Open. 2018 Jun 9;8(6):e022894
pubmed: 29886449
Ann Emerg Med. 2014 Dec;64(6):17A-19A
pubmed: 25606603
Health (London). 2022 Jul;26(4):431-456
pubmed: 33045861
Int J Speech Lang Pathol. 2014 Apr;16(2):159-68
pubmed: 23826849
J Pain Symptom Manage. 2000 Aug;20(2):130-9
pubmed: 10989251
Cochrane Database Syst Rev. 2018 Feb 22;2:MR000013
pubmed: 29468635
Int J Stroke. 2013 Apr;8(3):193-6
pubmed: 23130972
Clin Interv Aging. 2019 Feb 13;14:321-334
pubmed: 30863026
BMC Med. 2020 Jul 22;18(1):221
pubmed: 32693800
Trials. 2021 Jan 14;22(1):57
pubmed: 33446265
Contemp Clin Trials. 2020 Aug;95:106054
pubmed: 32526281
Nat Med. 2020 Sep;26(9):1328-1330
pubmed: 32651580
J Med Ethics. 2009 Jun;35(6):377-81
pubmed: 19482983
J Am Geriatr Soc. 2012 Mar;60(3):413-9
pubmed: 22288835
PLoS One. 2021 Sep 1;16(9):e0256697
pubmed: 34469482
Stroke. 2007 Nov;38(11):3076-83
pubmed: 17932334
Trials. 2019 Aug 05;20(1):474
pubmed: 31382999
BMJ Open. 2014 May 15;4(5):e005045
pubmed: 24833694

Auteurs

Amy M Russell (AM)

Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.

Victoria Shepherd (V)

Centre for Trials Research, Cardiff University, 4th floor Neuadd Meirionnydd, Heath Park, Cardiff, CF14 4YS, UK. ShepherdVL1@cardiff.ac.uk.

Kerry Woolfall (K)

Department of Public Health, Policy and Systems, Institute of Population Health, University of Liverpool, Liverpool, UK.

Bridget Young (B)

Department of Public Health, Policy and Systems, Institute of Population Health, University of Liverpool, Liverpool, UK.

Katie Gillies (K)

Health Services Research Unit, University of Aberdeen, Aberdeen, UK.

Anna Volkmer (A)

Department of Psychology and Language Sciences, University College London, London, UK.

Mark Jayes (M)

Department of Health Professions, Manchester Metropolitan University, Manchester, UK.

Richard Huxtable (R)

Centre for Ethics in Medicine, Population Health Science, Bristol Medical School, University of Bristol, Bristol, UK.

Alexander Perkins (A)

Department of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.

Nurulamin M Noor (NM)

Medical Research Council Clinical Trials Unit at University College London (MRC CTU at UCL), Institute of Clinical Trials and Methodology, University College London, London, UK.

Beverley Nickolls (B)

Centre for Evaluation and Methods, Wolfson Institute of Population Health, Queen Mary University London, London, UK.

Julia Wade (J)

Population Health Science, Bristol Medical School, University of Bristol, Bristol, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH